We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
-8.7%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$4.8B
AUM Growth
+$87.7M
Cap. Flow
+$861M
Cap. Flow %
17.92%
Top 10 Hldgs %
41.63%
Holding
117
New
20
Increased
33
Reduced
18
Closed
25

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$187M
2
ISRG icon
Intuitive Surgical
ISRG
+$94.9M
3
HUM icon
Humana
HUM
+$83.2M
4
BIIB icon
Biogen
BIIB
+$79.4M
5
UNH icon
UnitedHealth
UNH
+$65.8M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$123M
2
ARNA
Arena Pharmaceuticals Inc
ARNA
+$113M
3
LLY icon
Eli Lilly
LLY
+$95.2M
4
HOLX
Hologic
HOLX
+$81.5M
5
SGEN
Seagen Inc. Common Stock
SGEN
+$79.1M

Sector Composition

Rank Sector Weight
1 Healthcare 91.22%
2 Financials 0.49%
3 Technology 0.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PEN icon
51
Penumbra
PEN
$12.6B
$23.1M 0.48%
+104,000
New +$23.1M
SIBN icon
52
SI-BONE Inc
SIBN
$795M
$22.6M 0.47%
1,000,000
+12,600
+1% +$261K
VIR icon
53
Vir Biotechnology
VIR
$1.49B
$20.1M 0.42%
780,000
+80,000
+11% +$2.37M
VRDN icon
54
Viridian Therapeutics
VRDN
$2.15B
$19.2M 0.4%
1,040,000
-238,261
-19% -$4.58M
BPMC
55
DELISTED
Blueprint Medicines
BPMC
$18.6M 0.39%
291,184
-703,816
-71% -$50.5M
ALT icon
56
Altimmune
ALT
$581M
$17.4M 0.36%
2,865,000
+100,000
+4% +$736K
EPIX
57
DELISTED
ESSA Pharma
EPIX
$15.2M 0.32%
2,460,000
– –
SGEN
58
DELISTED
Seagen Inc. Common Stock
SGEN
$14.4M 0.3%
100,000
-585,000
-85% -$79.1M
LKFT
59
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.84B
$13.3M 0.28%
+215,000
New +$13.2M
IPSC icon
60
Century Therapeutics
IPSC
$370M
$10.9M 0.23%
865,000
+13,478
+2% +$179K
ALPN
61
DELISTED
Alpine Immune Sciences Inc
ALPN
$10.8M 0.23%
1,207,000
-138,000
-10% -$1.19M
APLS
62
DELISTED
Apellis Pharmaceuticals
APLS
$10.7M 0.22%
+210,000
New +$9.27M
ANTX icon
63
AN2 Therapeutics
ANTX
$169M
$10.4M 0.22%
+688,330
New +$10.4M
ERAS icon
64
Erasca
ERAS
$6.3B
$8.56M 0.18%
+995,000
New +$11.5M
S icon
65
SentinelOne
S
$6.29B
$7.92M 0.17%
204,500
-3,500
-2% -$143K
CYT
66
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$6.97M 0.15%
1,850,000
+462
+0% +$2.63K
PHAS
67
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$5.82M 0.12%
4,405,000
– –
CMAX
68
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
$5.64M 0.12%
25,178
-2,402
-9% -$498K
TNGX icon
69
Tango Therapeutics
TNGX
$4.34B
$5.46M 0.11%
721,000
+16,000
+2% +$139K
HYPR icon
70
Hyperfine
HYPR
$90.9M
$5.32M 0.11%
1,503,754
-10,656
-0.7% -$44K
MSAC
71
DELISTED
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
$5.09M 0.11%
520,000
– –
SNTI icon
72
Senti Biosciences Holdings
SNTI
$11.9M
$4.93M 0.1%
50,000
– –
BLSA
73
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$4.93M 0.1%
500,000
– –
ARYD
74
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$4.9M 0.1%
500,000
– –
PANA
75
DELISTED
Panacea Acquisition Corp. II Class A Ordinary Shares
PANA
$4.88M 0.1%
500,000
– –
1 2
3
4 5

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q1 2022 Portfolio in Review

As of Q1 2022, Avidity Partners Management held 117 positions worth $4.8B, up 1.9% from $4.71B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Avidity Partners Management deployed $861M of net new capital in Q1 2022, opening 20 new positions and adding to 33 existing holdings. Its largest new stake was Merck: 2,370,000 shares worth $194M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 98% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Seagen Inc. Common Stock, an estimated $79.1M trimmed.

  • Avidity Partners Management's largest Q1 2022 buy was Merck: 2,370,000 shares worth $194M.
  • Avidity Partners Management added most to UnitedHealth in Q1 2022, an estimated $65.8M increase.
  • Avidity Partners Management's biggest Q1 2022 reduction was Seagen Inc. Common Stock, cutting an estimated $79.1M.
  • Avidity Partners Management fully exited Pfizer in Q1 2022, selling an estimated $123M.
  • Avidity Partners Management's ten largest holdings make up 42% of its $4.8B portfolio in Q1 2022.
  • Avidity Partners Management opened 20 new positions and closed 25 in Q1 2022.
  • Avidity Partners Management's portfolio value rose 1.9% quarter-over-quarter to $4.8B.

Based on Avidity Partners Management's 13F filing for Q1 2022, filed 16 May 2022.